Skip to content
Head to head

Incyte vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: INCY · VRTX

Updated 3 minutes ago

1-year performance, rebased to 100

INCY +10.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
INCYVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price114.63515.02
Change today-1.07%-1.08%
1-year return+12.6%+22.0%
Market cap$23.36B$130.58B
52-week range89.25 – 132.60412.27 – 568.67
Valuation
P/E (TTM)58.4833.14
P/E percentile, own 5-yr range79th99th
P/B4.146.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)6.4115.32
Net profit (TTM)$1.31B$3.88B
Revenue (TTM)$6.01B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+14.0%+11.8%
Gross margin92.7%85.5%
Operating margin11.7%33.1%
Net margin6.7%30.7%
Free cash flow (TTM)$679.87M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership101.1%96.8%
Insider activity (12mo)33 buy / 17 sell28 buy / 22 sell
Short interest (% of float)5.2%1.9%
Analyst consensus59% buy / 41% hold (17)95% buy / 5% hold (21)
Analyst price target$137 (+19%)$624 (+21%)
StockVane view
StockVane Quant RatingC (56)C (68)
Company
Employees2,8446,400
Founded19911989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.